

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Xgeva (denosumab)

PHYSICI	AN INFORMAT	PATIENT INFORMATION					
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with				
Specialty: * DEA, N		A, NPI or TIN:	the outcome of our review unless all asterisked (*) items on this form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID:	* Date of		th:	
Office Fax:			* Patient Street Address:				
Office Street Address:			City: State:			Zip:	
City:	State:	Zip:	Patient Phone:				
Urgency: ☐ Standard	☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)						
Medication requested: ☐ Xgeva 120mg ICD10:							
Dose:	Freque	Frequency of therapy: Duration of therapy:					
Is this a new start or does your patient have a previous history of using the requested medication? If patient has been taking samples, please pick "new start." □ new start □ Previous history of using Xgeva							
Where will this medic ☐ Accredo Specialty Pha ☐ Prescriber's office stor ☐ Other (please specify) **Medication orders can be NCPDP 4436920), Fax 86	armacy** ck (billing on a m : ce placed with A	Retail pharmacy Home Health / Home Infusion vendor **Cigna's nationally preferred specialty pharmacy - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code):							
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Diagnosis related to use: ☐ Bone Metastases from Solid Tumors (examples include breast cancer, prostate cancer, and non-small cell lung cancer) – Prevention of Skeletal-Related Events ☐ Giant Cell Tumor of Bone (GCTB) ☐ Hypercalcemia of Malignancy ☐ Multiple Myeloma – Prevention of Skeletal-Related Events ☐ other (please specify):							
Clinical Information:							
(if Bone Metastases from	Solid Tumors) [e bone metastases?			☐ Yes ☐ No		
(if Bone Metastases from	Solid Tumors) D	e prostate cancer?			☐ Yes ☐ No		
(if Bone Metastases from Solid Tumors [prostate cancer]) Is the patient's disease considered to be castration-resistant (meaning it progressed after treatment with hormonal therapy [examples of hormonal therapies for prostate cancer include Lupron Depot (leuprolide for depot suspension), Eligard (leuprolide acetate for injectable suspension), Trelstar (triptorelin pamoate for injectable suspension) or Zoladex (goserelin implant)] or after surgical castration [for example, bilateral orchiectomy])?							

(Bone Metastases from Solid Tumors or MM) Does your patient have renal impairment (creatinine clearance less that	ın 30 mL/min)? ☐ Yes ☐ No						
(if Hypercalcemia of Malignancy) Does the patient currently have a malignancy?	☐ Yes ☐ No						
(if Hypercalcemia of Malignancy) Does the patient have an albumin-corrected calcium (cCa) of 11.5 mg/dL or higher?	? ☐ Yes ☐ No						
(Bone Metastases from Solid Tumors or MM) The covered alternative is zoledronic acid injection (Zometa). If your partial drug, please provide drug strength, date(s) taken and for how long, and what the documented results were of taking any intolerances or adverse reactions your patient experienced. If your patient has NOT tried this drug, please provide patient can't try this alternative.	this drug, including						
(if Bone Metastases from Solid Tumors or MM) Per the information provided above, which of the following is true for to the covered alternative?	your patient in regard						
☐ The patient tried the alternative, but it didn't work. ☐ The patient tried the alternative, but they did not tolerate it. ☐ The patient cannot try the alternative because of a contraindication to this drug. ☐ Other							
(Bone Metastases from Solid Tumors or MM) Is this medication prescribed by, or in consultation with, a hematologist	or an oncologist? ☐ Yes ☐ No						
Additional pertinent information: (including prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently)							
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the lits designees may perform a routine audit and request the medical information necessary to verify the accuracy or reported on this form.							
Prescriber Signature: Date:							
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureSc	ripts in your EHR.						
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it	is important that you						

response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005